Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Feature articles “DDS medicines and their clinical developments” Editor:Hiroshi Kikuchi
Development of Zevalin and future prospect of radioimmunotherapy
Masahiko Tokura, Yoshifumi Yabuuchi
Author information
Keywords: Armed antibody, Zevalin, Radioimmunotherapy, Cross-fire effect, Cadherin-3
JOURNAL FREE ACCESS

2013 Volume 28 Issue 3 Pages 197-204

Details
Download PDF (717K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
Zevalin, the first approved radioimmunotherapeutic agent for Non-hodgkin's lymphoma, is not only highly effective but also kind treatment even for elderly patients. In this review, we summarize development of Zevalin and future prospect of radioimmunotherapy (RIT), and introduce our candidate as a novel radioimmunotherapeutic agent for NSCLC treatment. Prospective selection of patients responds to RIT will be essential for approval in oncology.
Content from these authors
© 2013 Japan Society of Drug Delivery System
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top